患有心血管疾病的患者服用质子抑制剂的不良事件
Aitor Lanas-Gimeno1, Ángel Lanas2,3,4,5
1Servicio de Aparato Digestivo, Hospital de 12 de Octubre, Madrid, Spain.
Expert opinion on drug safety
|October 2, 2024
概括
质子抑制剂 (PPI) 可能会增加心血管风险,特别是在接受抗血小板治疗的患者中. 需要进一步的研究来探索潜在的联系,包括由PPI引起的贫血.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 质子抑制剂 (PPI) 广泛用于与酸有关的疾病.
- 有关长期使用PPI的潜在严重不良事件,包括心血管事件,存在担忧.
研究的目的:
- 在高风险心血管患者中审查与PPI使用相关的心血管不良事件.
- 探索PPI,抗血小板治疗和心血管结果之间的复杂关系.
主要方法:
- 一个对现有文献的全面审查.
- 在PubMed.com上进行了结构化的文献搜索.
主要成果:
- 观察性研究表明,长期使用PPI会增加心血管风险,但临床试验和元分析在很大程度上是不确定的.
- 潜在的与丁皮里丁代谢相互作用是一个有争议的机制.
- 贫血,可能与PPI诱导的肠道微生物群变化有关,是这些患者的常见事件和心血管风险因素.
结论:
- 防护剂和心血管事件之间的联系仍然不确定,需要进一步调查,而不仅仅是直接的药物相互作用.
- 贫血作为显著因素出现,在同时使用PPI和抗血小板治疗的患者中需要注意.
相关概念视频
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
360
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
360
Peptic Ulcer Disease IV: Management
74
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
74
Peptic Ulcer Disease I: Introduction
141
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
141
Pharmacovigilance
784
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
784
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
409
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
409
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
356
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
356


